Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 5/20 | 0.59 |
| ▸ | MEN1 | O00255 | 3/20 | 0.59 |
| ▸ | GFER | P55789 | 1/20 | 0.59 |
| ▸ | MAPT | P10636 | 1/20 | 0.59 |
| ▸ | SNCA | P37840 | 1/20 | 0.54 |
| ▸ | GAA | P10253 | 1/20 | 0.53 |
| ▸ | ABCG2 | Q9UNQ0 | 5/20 | 0.53 |
| ▸ | F10 | P00742 | 1/20 | 0.50 |
| ▸ | CA1 | P00915 | 1/20 | 0.50 |
| ▸ | CA9 | Q16790 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | PTPN7 | P35236 | 1/20 | 0.48 |
| ▸ | PTPN22 | Q9Y2R2 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7242995 | 0.85 | KMT2A (0.58) | KMT2AMEN1GFERGAAABCG2 | |
| SCHEMBL7244555 | 0.84 | F10 (0.60) | KMT2AMEN1MAPTGAAABCG2 | |
| SCHEMBL7868603 | 0.84 | KMT2A (0.57) | KMT2AMEN1GAAABCG2F10 | |
| SCHEMBL5223570 | 0.83 | KMT2A (0.56) | KMT2AMEN1GAAABCG2F10 | |
| SCHEMBL7245504 | 0.76 | MAPT (0.69) | KMT2AMEN1MAPTSNCAGAA | |
| SCHEMBL14802407 | 0.76 | MAPT (0.66) | KMT2AMEN1MAPTSNCAGAA | |
| SCHEMBL14802389 | 0.75 | SMN1; SMN2 (0.63) | KMT2AMEN1MAPTSNCAABCG2 | |
| SCHEMBL7251629 | 0.74 | MAPT (0.56) | KMT2AMEN1MAPTGAAF10 | |
| SCHEMBL9113889 | 0.74 | CA12 (0.72) | KMT2AMEN1MAPTCA1CA9 | |
| SCHEMBL7237063 | 0.74 | HTT (0.76) | KMT2AMEN1MAPTSNCAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6605626-B2 | Benzamide inhibitors of factor Xa | ELI LILLY AND COMPANY | 2003-08-12 | — | — | US | disclosed |
| US-20020120007-A1 | Benzamide inhibitors of factor Xa | BEIGHT DOUGLAS WADE (US) | 2002-08-29 | — | — | US | disclosed |
| US-6313122-B1 | AS INHIBITORS OF FACTOR XA AND ARE USED AS ANTICOAGULANTS IN MAMMALS | ELI LILLY AND COMPANY | 2001-11-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020120007-A1 | Benzamide inhibitors of factor Xa | TFPI, F11, F12 | KMT2A 2083/4885MEN1 1119/4885GFER 1610/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.